Navigation Links
Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis

A Drug's Safety Profile is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., April 21 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that in addition to surveyed infectious disease specialists' prediction that empiric coverage of methicillin-resistant Staphylococcus aureus (MRSA) will increase, they foresee greater use of parenteral outpatient therapy (intravenous or intramuscular injection) for the treatment of osteomyelitis. Osteomyelitis is an infection of bone or bone marrow caused by bacterial infections.

"Osteomyelitis often requires an extended duration of antibiotic therapy after hospital discharge and many patients are prescribed an injectable agent," stated Lisa Arias, analyst at Decision Resources. "Nearly one-third of surveyed physicians expect increased use of parenteral antibiotic therapy in the next five years."

The new report entitled Hospital Anti-Infectives Insight Series: Osteomyelitis also finds that although surveyed infectious disease specialists look for a range of attributes when prescribing an antibiotic for osteomyelitis, the leading attribute, by far, is the drug's safety profile when administered over a long period of time -- 77 percent of surveyed physicians cited this attribute as extremely important. Physicians also look for an antibiotic that can be dosed, administered and monitored easily in the outpatient setting. Other important factors are the drug's ability to penetrate bone and activity against MRSA.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales              Elizabeth Marshall
    Decision Resources           Decision Resources, Inc.
    781-296-2691                 781-296-2563

SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
9. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... 2015 --> --> ... to find optimal contrast weighting of MRI for patients ... signed a research agreement with SyntheticMR in order to use ... it is possible to generate multiple contrast images from a ... has left, thus making it possible to both fine tune ...
Breaking Medicine Technology: